Search Patents
  • USE OF VIRAL VECTORS FOR CORONAVIRUS VACCINE PRODUCTION
    Publication number: 20230142780
    Abstract: Provided herein are compositions that includes AAVs and AAV vectors that include a sequence encoding a SARS-CoV-2 polypeptide or a fragment thereof. Also provided herein are methods and materials for making and using AAVs and AAV vectors to generate immunity to a coronavirus in a subject.
    Type: Application
    Filed: April 9, 2021
    Publication date: May 11, 2023
    Applicants: 4MVac LLC, Trustees of the University of Pennsylvania, Johnson & Johnson, Inc.
    Inventors: Hansell Hall Stedman, Geoffrey Tabin, Charles R. Bridges
  • Compositions and methods for detecting severe acute respiratory syndrome coronavirus
    Patent number: 7129042
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: October 31, 2006
    Assignees: Diagnostic Hybrids, Inc., Health Research Incorporated
    Inventors: Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick
  • CIRCULAR RNA VACCINES AND METHODS OF USE THEREOF
    Publication number: 20230346921
    Abstract: The present application provides circular RNAs (circRNAs) encoding therapeutic polyeptides (e.g., an antigenic polypeptide, a functional protein, a receptor protein, or a targeting protein). In some embodiments, the present application provides circRNA vaccines against a coronavirus such as SARS-CoV-2. In some embodiments, the circRNA vaccine comprises a circRNA comprising a nucleic acid sequence encoding an antigenic polypeptide comprising a Spike (S) protein or a fragment thereof of a coronavirus. Also provided are methods of treating or preventing a disease or condition using the circRNAs or compositions thereof.
    Type: Application
    Filed: August 20, 2021
    Publication date: November 2, 2023
    Inventors: Wensheng WEI, Liang QU, Zongyi YI
  • CORONAVIRUS VACCINE
    Publication number: 20230158137
    Abstract: The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in a subject. The polypeptides and vaccines comprise B cell epitopes and cytotoxic and helper T cell epitopes that are immunogenic in a high percentage of subjects in the human population.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 25, 2023
    Inventors: Zsolt Csiszovszki, Orsolya Lörincz, Levente Molnár, Péter Páles, Katalin Pántya, Eszter Somogyi, József Tóth, Eniko Rita Toke
  • NUCLEIC ACID BASED COMBINATION VACCINES
    Publication number: 20220211841
    Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).
    Type: Application
    Filed: February 7, 2022
    Publication date: July 7, 2022
    Applicant: CureVac AG
    Inventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
  • CORONAVIRUS VACCINE COMPOSITIONS AND METHODS
    Publication number: 20240115691
    Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
    Type: Application
    Filed: June 30, 2023
    Publication date: April 11, 2024
    Inventors: Sean Michael SULLIVAN, Daiki MATSUDA, Kiyoshi TACHIKAWA, Padmanabh CHIVUKULA, Priya Prakash KARMALI, Jared Henry DAVIS, Yanjie BAO, Amit SAGI
  • CORONAVIRUS VACCINE COMPOSITIONS AND METHODS
    Publication number: 20210290756
    Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
    Type: Application
    Filed: March 9, 2021
    Publication date: September 23, 2021
    Inventors: Sean Michael SULLIVAN, Daiki MATSUDA, Kiyoshi TACHIKAWA, Padmanabh CHIVUKULA, Priya Prakash KARMALI, Jared Henry DAVIS, Yanjie BAO, Amit SAGI
  • NUCLEIC ACID BASED COMBINATION VACCINES
    Publication number: 20220249654
    Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).
    Type: Application
    Filed: February 7, 2022
    Publication date: August 11, 2022
    Applicant: CureVac AG
    Inventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
  • NUCLEIC ACID BASED COMBINATION VACCINES
    Publication number: 20220211838
    Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).
    Type: Application
    Filed: February 7, 2022
    Publication date: July 7, 2022
    Applicant: CureVac AG
    Inventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
  • Canine coronavirus vaccine
    Patent number: 4904468
    Abstract: A vaccine for protecting canine animals from disease caused by infection with canine corona virus (CCV) which comprises an effective amount of the cell-associated CCV peplomer protein. A polyvalent vaccine comprising an effective amount of cell-associated CCV peplomer protein and an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed.
    Type: Grant
    Filed: June 8, 1987
    Date of Patent: February 27, 1990
    Assignee: Norden Laboratories, Inc.
    Inventors: Michael A. Gill, Stephen W. May
  • RNA vaccine against SARS-CoV-2 variants
    Publication number: 20220202930
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 30, 2022
    Applicants: CureVac AG, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROSSE, Dominik VAHRENHORST, Susanne RAUCH
  • MODIFIED POLYNUCLEOTIDES ENCODING THE SARS-COV-2 SPIKE PROTEIN FOR SAFER DESIGNS OF CORONAVIRUS VACCINES
    Publication number: 20240100152
    Abstract: Recombinant polynucleotides including a nucleic acid sequence encoding an engineered SARS-CoV-2 spike protein (S12) or an immunogenic fragment thereof, in which the engineered spike protein or immunogenic fragment includes one or more mutations in the S2 segment of the S12 ectodomain. Vaccines, pharmaceutical compositions, and methods of use of the polynucleotides, vaccines, and pharmaceutical compositions in treating, alleviating, or managing SARS-CoV-2 infection and/or one or more symptoms thereof.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 28, 2024
    Inventors: Pei Tang, Tommy Stevens Tillman, Yan Xu
  • RNA VACCINE AGAINST SARS-COV-2 VARIANTS
    Publication number: 20240156946
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: December 21, 2021
    Publication date: May 16, 2024
    Applicants: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
  • Nucleic Acid Based Vaccine
    Publication number: 20240156949
    Abstract: The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.
    Type: Application
    Filed: October 26, 2023
    Publication date: May 16, 2024
    Applicants: GlaxoSmithKline Biologicals SA, CureVac SE
    Inventors: Benjamin PETSCH, Dominik VAHRENHORST, Diego CHAVES MORENO, Janina GERGEN, Jessica Michelle DEVANT, Kristina KOVACIKOVA, Hans Wolfgang GROßE
  • RNA vaccine against SARS-CoV-2 variants
    Publication number: 20220331422
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: May 31, 2022
    Publication date: October 20, 2022
    Applicants: CureVac AG, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
  • PORCINE CORONAVIRUS VACCINES
    Publication number: 20200038504
    Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.
    Type: Application
    Filed: January 26, 2018
    Publication date: February 6, 2020
    Inventors: Scott ACKERMAN, Joseph Ralph HERMANN, Luis Alejandro HERNANDEZ, Lea Ann HOBBS, Arun V. IYER, Sean O'CONNER, Abby Rea PATTERSON, Eric Martin VAUGHN, Joseph Gilbert VICTORIA
  • RNA vaccine against SARS-CoV-2 variants
    Patent number: 11918643
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: March 5, 2024
    Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
  • RNA vaccine against SARS-CoV-2 variants
    Patent number: 11872280
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: May 31, 2022
    Date of Patent: January 16, 2024
    Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
  • Coronavirus vaccine compositions and methods
    Patent number: 11744887
    Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: September 5, 2023
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Sean Michael Sullivan, Daiki Matsuda, Kiyoshi Tachikawa, Padmanabh Chivukula, Priya Prakash Karmali, Jared Henry Davis, Yanjie Bao, Amit Sagi
  • NOVEL CORONAVIRUS S PROTEIN DOUBLE-REGION SUBUNIT NANO-VACCINE BASED ON BACTERIAL COMPLEX
    Publication number: 20230090422
    Abstract: The present application is related to a novel coronavirus S protein double-region subunit nano-vaccine based on a bacterial complex. In the present invention, a receptor binding domain (RBD) and a fusion peptide (FP) of a virus are used together as double antigens, and are connected to a bacterial complex (such as PF_Ferritin or Lumazine Synthase (LS)) to form a fusion protein, so as to achieve antigen multimerization; and then expression is performed by using a eukaryotic cell expression system, and a 24-mer nano-antigen or a 60-mer nano-antigen can be formed by means of self-assembly action. The solution can overcome the defect of insufficient immunogenicity of an RBD monomer. The obtained vaccine can significantly increase the level of a neutralizing antibody against a virus in a host, and the resulting antibody has the capability of strongly blocking a virus from invading a target cell.
    Type: Application
    Filed: March 11, 2020
    Publication date: March 23, 2023
    Applicant: SUN YAT-SEN UNIVERSITY
    Inventors: Hui ZHANG, Xiancai MA, Fan ZOU, Yaochang YUAN, Rong LI, Xu ZHANG
Narrow Results

Filter by US Classification